PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för AZD5153. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

16 hits

Bibliografisk träff 2023-10-01

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma.

Hamilton EP, Wang JS, Oza AM, Patel MR, Ulahannan SV, Bauer T, Karlix JL, Zeron-Medina J, Fabbri G, Marco-Casanova P, Moorthy G, Hattersley MM, Littlewood GM, Mitchell P, Saeh J, Pouliot GP, Moore KN.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1158/1535-7163.mct-23-0065

Bibliografisk träff 2023-09-01

BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5.

Oien DB, Sharma S, Hattersley MM, DuPont M, Criscione SW, Prickett L, Goeppert AU, Drew L, Yao Y, Zhang J, Chan HM.

Blood Adv · research support, non-u.s. gov't; research-article; journal article · DOI 10.1182/bloodadvances.2022009257

Bibliografisk träff 2023-02-08

Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer.

Huang Y, Liu C, You L, Li X, Chen G, Fan J.

J Cell Mol Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/jcmm.17683

Bibliografisk träff 2022-05-27

Erratum: BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor: Erratum.

Zhang P, Li R, Xiao H, Liu W, Zeng X, Xie G, Yang W, Shi L, Yin Y, Tao K.

Int J Biol Sci · published erratum; correction · DOI 10.7150/ijbs.73868

Bibliografisk träff 2022-04-11

MUS81 Inhibition Enhances the Anticancer Efficacy of Talazoparib by Impairing ATR/CHK1 Signaling Pathway in Gastric Cancer.

Wang T, Zhang P, Li C, Liu W, Shen Q, Yang L, Xie G, Bai J, Li R, Tao K, Yin Y.

Front Oncol · research-article; journal article · DOI 10.3389/fonc.2022.844135

Bibliografisk träff 2022-03-24

AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells.

Lin CH, Kuo JC, Li D, Koenig AB, Pan A, Yan P, Bai XF, Lee RJ, Ghoshal K.

Front Cell Dev Biol · research-article; journal article · DOI 10.3389/fcell.2022.853652

Bibliografisk träff 2021-12-20

AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway.

Liu C, Huang Y, Qin T, You L, Lu F, Hu D, Xiao R, Qin X, Guo E, Yang B, Li X, Fan J, Li X, Fu Y, Liu S, Wang Z, Dou Y, Wang W, Li W, Yang X, Liu J, Peng W, Zhang L, Cui Y, Sun C, Chen G.

Cancer Lett · journal article · DOI 10.1016/j.canlet.2021.12.021

Bibliografisk träff 2021-10-24

Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.

Woods AD, Berlow NE, Ortiz MV, Dela Cruz F, Siddiquee A, Coutinho DF, Purohit R, Freier KET, Michalek JE, Lathara M, Matlock K, Srivivasa G, Royer-Pokora B, Veselska R, Kung AL, Keller C.

Pediatr Blood Cancer · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/pbc.29401

Bibliografisk träff 2020-02-28

BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages.

Li X, Fu Y, Yang B, Guo E, Wu Y, Huang J, Zhang X, Xiao R, Li K, Wang B, Hu J, Sun C, Chen G.

Front Immunol · research support, non-u.s. gov't; research-article; journal article · DOI 10.3389/fimmu.2020.00089

Bibliografisk träff 2019-07-21

BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.

Zhang P, Li R, Xiao H, Liu W, Zeng X, Xie G, Yang W, Shi L, Yin Y, Tao K.

Int J Biol Sci · research support, non-u.s. gov't; research-article; journal article · DOI 10.7150/ijbs.34162

Bibliografisk träff 2018-10-11

AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo.

Shen G, Chen J, Zhou Y, Wang Z, Ma Z, Xu C, Jiang M.

Cell Physiol Biochem · journal article · DOI 10.1159/000494244

Bibliografisk träff 2018-06-21

Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.

Takimoto-Shimomura T, Tsukamoto T, Maegawa S, Fujibayashi Y, Matsumura-Kimoto Y, Mizuno Y, Chinen Y, Shimura Y, Mizutani S, Horiike S, Taniwaki M, Kobayashi T, Kuroda J.

Invest New Drugs · research support, non-u.s. gov't; journal article · DOI 10.1007/s10637-018-0623-8

Bibliografisk träff 2018-03-31

AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo.

Xu K, Chen D, Qian D, Zhang S, Zhang Y, Guo S, Ma Z, Wang S.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2018.03.184

Bibliografisk träff 2017-05-27

Translational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor.

Collins TA, Hattersley MM, Yates J, Clark E, Mondal M, Mettetal JT.

CPT Pharmacometrics Syst Pharmacol · research-article; journal article · DOI 10.1002/psp4.12194

Bibliografisk träff 2016-08-29

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.

Rhyasen GW, Hattersley MM, Yao Y, Dulak A, Wang W, Petteruti P, Dale IL, Boiko S, Cheung T, Zhang J, Wen S, Castriotta L, Lawson D, Collins M, Bao L, Ahdesmaki MJ, Walker G, O'Connor G, Yeh TC, Rabow AA, Dry JR, Reimer C, Lyne P, Mills GB, Fawell SE, Waring MJ, Zinda M, Clark E, Chen H.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-16-0141

Bibliografisk träff 2016-08-24

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).

Bradbury RH, Callis R, Carr GR, Chen H, Clark E, Feron L, Glossop S, Graham MA, Hattersley M, Jones C, Lamont SG, Ouvry G, Patel A, Patel J, Rabow AA, Roberts CA, Stokes S, Stratton N, Walker GE, Ward L, Whalley D, Whittaker D, Wrigley G, Waring MJ.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.6b00070